Decoglurant (
INN) (code name RG1578, RO4995819) is a
negative allosteric modulator
In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimulus. Some of them, like benzodiazepines, are drugs. The site that an allosteric modulator binds t ...
of the
mGlu2 and
mGlu3 receptors which was under development by
Roche
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX ...
for the
adjunctive treatment of
major depressive disorder
Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Intro ...
.
Decoglurant progressed as far as
phase II clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s
but was ultimately discontinued from further development due to disappointing efficacy results.
See also
*
Basimglurant
*
RO4491533
RO-4491533 is a drug developed by Hoffmann-La Roche which acts as a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors ( mGluR2/3), being equipotent at mGluR2 and mGluR3 but without activity ...
References
External links
Decoglurant – AdisInsight – Springer
Abandoned drugs
MGlu2 receptor antagonists
MGlu3 receptor antagonists
Trifluoromethyl compounds
Alkyne derivatives
Aminopyridines
{{nervous-system-drug-stub